When do paediatric patients with familial hypercholesterolemia need statin therapy?

Area of Science:

• Cardiology
• Pediatrics
• Genetics

Background:

• Familial hypercholesterolemia (FH) is a common autosomal dominant disorder.
• Elevated LDL cholesterol in FH begins in early childhood, increasing risks of myocardial infarction and stroke.
• Early identification and treatment of lipid disorders in children are crucial for mitigating long-term cardiovascular risks.

Purpose of the Study:

• To assess the utility of ApoB/ApoA index, carotid intima-media thickness (IMT), and e-tracking in guiding statin therapy for pediatric FH patients.
• To evaluate the effectiveness of dietary changes and statin therapy in managing lipid levels and cardiovascular risk markers in children with FH.

Main Methods:

• Prospective and retrospective study of 57 pediatric FH patients (aged 1-17 years) confirmed by molecular testing.
• Measurement of lipid profiles, ApoA, ApoB, carotid IMT (ultrasound), and arterial stiffness (e-tracking).
• Monitoring dietary treatment efficacy in 40 patients and combination therapy in 27 patients over 12 months.

Main Results:

• Pediatric FH patients exhibited high total and LDL cholesterol levels (287±67 mg/dL and 213±73 mg/dL).
• 34.37% had an elevated ApoB/ApoA index, and 100% showed vascular abnormalities on IMT or e-tracking.
• Six months of diet reduced cholesterol by ~7%, while 12 months of statin therapy (average 10.42±2.49 mg) lowered levels but remained above target, with no significant adverse effects.

Conclusions:

• Elevated ApoB/ApoA index and vascular abnormalities (IMT, e-tracking) in pediatric FH patients indicate an increased cardiovascular risk.
• These findings support the initiation of statin therapy in children diagnosed with FH based on these risk indicators.